

1 **Rapid Biphasic Decay of Intact and Defective HIV DNA**
2 **Reservoir During Acute Treated HIV Disease**

3
4 Alton Barbehenn¹, Lei Shi², Junzhe Shao², Rebecca Hoh¹, Heather M. Hartig¹, Vivian Pae¹,
5 Sannidhi Sarvadhavabhatla¹, Sophia Donaire¹, Caroline Sheikhzadeh¹, Jeffrey Milush⁵, Gregory
6 M. Laird³, Mignot Mathias³, Kristen Ritter³, Michael J. Peluso¹, Jeffrey Martin⁴, Frederick Hecht¹,
7 Christopher Pilcher¹, Stephanie E. Cohen^{1,6}, Susan Buchbinder⁶, Diane Havlir¹, Monica
8 Gandhi¹, Timothy J. Henrich⁵, Hiroyu Hatano¹, Jingshen Wang², Steven G. Deeks¹, and Sulggi
9 A. Lee*¹

10
11 ¹Department of Medicine, Division of HIV, Infectious Diseases & Global Medicine, University of
12 California San Francisco, San Francisco, CA 94110, USA. ²Department of Biostatistics,
13 University of California Berkeley, Berkeley, CA 94110, USA. ³AcceleVirDiagnostics, Baltimore,
14 MD 21202, USA. ⁴Department of Biostatistics & Epidemiology, University of California San
15 Francisco, CA 94158, USA. ⁵Department of Medicine, Division of Experimental Medicine,
16 University of California San Francisco, San Francisco, CA 94110, USA. ⁶San Francisco
17 Department of Public Health, San Francisco, CA 94102, USA.

18
19 #Co-Lead Authors: Alton Barbehenn and Lei Shi

20 *Corresponding Author: sulggi.lee@ucsf.edu

21 **ABSTRACT**

22 Despite antiretroviral therapy (ART), HIV persists in latently-infected cells (“the reservoir”) which
23 decay slowly over time. Here, leveraging >500 longitudinal samples from 67 people with HIV
24 (PWH) treated during acute infection, we developed a novel mathematical model to predict
25 reservoir decay from peripheral CD4+ T cells. Nonlinear generalized additive models
26 demonstrated rapid biphasic decay of intact DNA (week 0-5: $t_{1/2}$ ~2.83 weeks; week 5-24:
27 $t_{1/2}$ ~15.4 weeks) that extended out to 1 year. These estimates were ~5-fold faster than prior
28 decay estimates among chronic treated PWH. Defective DNA had a similar biphasic pattern, but
29 data were more variable. Predicted intact and defective decay rates were faster for PWH with
30 earlier timing of ART initiation, higher initial CD4+ T cell count, and lower pre-ART viral load.
31 These data add to our limited understanding of HIV reservoir decay at the time of ART initiation,
32 informing future curative strategies targeting this critical time.

33

34 Abstract Word Count (limit 150): 148

35

36 **Title Word Count** (max 15): 15

37 **Manuscript Word Count** (5,000; Methods 3,000 words): 4,938

38 **Keywords:** acute HIV; antiretroviral therapy (ART); HIV reservoir decay; pre-exposure
39 prophylaxis (PrEP)

40 **CONFLICTS:** The authors do not have a commercial or other association that might pose a
41 conflict of interest.

42 **FUNDING:** This work was supported in part by the National Institutes of Health: K23GM112526
43 (SAL), the DARE Collaboratory (UM1AI164560; SGD), the AcceleVirDx HIV Reservoir Testing
44 Resource (U24AI143502; GML), and NIH/NIAID R01A141003 (TJH). This work was also
45 supported by the amfAR Research Consortium on HIV Eradication a.k.a. ARCHE (108072-50-
46 RGRL; SGD), the Bill & Melinda Gates Foundation (INV-002703; SGD), and investigator-
47 initiated research grants from ViiV Healthcare (A126326; SAL) and Gilead Sciences (IN-US-
48 236-1354; SAL). The content of this publication does not necessarily reflect the views or policies
49 of the Department of Health and Human Services, the San Francisco Department of Health, nor
50 does mention of trade names, commercial products, or organizations imply endorsement by the
51 U.S. Government. The funders had no role in study design, data collection and analysis,
52 decision to publish, or preparation of the manuscript.

53 **Previous presentation:** Preliminary data were presented in July 2023, as a poster presentation
54 at the International AIDS Society (IAS) conference in Brisbane, Australia.

55 **Reprints:** Reprint requests can be directed to Dr. Sulggi Lee, the corresponding author (contact
56 information above).

57 **Acknowledgements:**

58 The authors wish to acknowledge the participation of all the study participants who contributed
59 to this work as well as the clinical research staff of the UCSF Treat Acute HIV and SCOPE

60 cohorts who made this research possible. All funders had no role in study design, data
61 collection and analysis, decision to publish, or preparation of the manuscript. All authors
62 provided critical feedback in finalizing the report. SGD, HH, and SAL conceived and designed
63 the study. SGD, HH, and SAL obtained funding to support the clinical enrollment of study
64 participants, and SAL and SGD obtained funding to support characterization of the HIV
65 reservoir. SEC, SB, DH, and MG facilitated coordination with San Francisco Department of
66 Public Health and Ward 86 clinical services to link patients into care and provided critical
67 feedback on the clinical management of acute HIV. SAL, RH, SGD, TJH, HMH, SS, SD, and VP
68 coordinated the collection, management, and quality control processes for the clinical data, and
69 SAL, SGD, JM, FH, and CP provided biospecimens. JM and TJH performed biospecimen
70 processing, GML, MM, and KR performed the HIV reservoir assays. LS developed the initial
71 decay models, under the guidance of SAL and JW, and AB and SAL further modified these
72 models under the guidance of JW, LS, and JS. GML, MM, KR, LS, JS, JW, and SAL analyzed
73 the HIV reservoir data. AB, SAL, LS, JS, JW, SS, SD, VP, and CS performed data visualization
74 for the manuscript. SAL and AB wrote the report with critical feedback from LS, JW, and the
75 additional authors.

76 INTRODUCTION

77 While antiretroviral therapy (ART) is able to suppress virus to undetectable levels, virus
78 rapidly rebounds from latently-infected cells (“the HIV reservoir”) within weeks of ART
79 interruption and is thus, not a cure.¹⁻⁸ Thus, a major goal is to eradicate and/or accelerate the
80 decay of the reservoir in order to achieve clinical remission. However, HIV cure trials to date
81 have largely failed to demonstrate a clinically meaningful reduction in the size of the HIV
82 reservoir and/or lead to sustained ART-free remission.⁹⁻¹² The majority of these trials have
83 included people with HIV (PWH) treated during chronic infection long after reservoir
84 establishment (i.e., several years after initiating ART).¹³⁻¹⁸ Recent combination trials (e.g.,
85 broadly neutralizing antibodies given with ART) have yielded more promising results, and a few
86 participants have demonstrated extended post-intervention viral control,¹⁹⁻²¹ but the mechanisms
87 by which these participants have enhanced viral control remain unclear.

88 Individuals who initiate ART “earlier” (<6 months after infection) are more likely to
89 become “post-treatment controllers” (PTCs), demonstrating ART-free viral control after a period
90 of initial ART suppression.²² PWH treated during chronic HIV often have larger reservoirs²³⁻³⁰
91 and exhausted/dysfunctional immune responses³¹⁻³³ (due to prolonged periods of untreated HIV
92 infection). Thus, different host factors, such as timing of ART initiation, initial CD4+ T cell count,
93 or pre-ART HIV viral load, may have profound impact on HIV reservoir decay rates, and yet
94 there are limited reservoir decay modeling studies accounting for these factors. While there
95 have now been a handful of studies modeling how quickly the HIV reservoir decays during
96 prolonged ART (~20 years),³⁴⁻³⁷ there have been fewer studies modeling decay rates after acute
97 treated HIV,³⁸⁻⁴⁰ and none directly performing mathematical modeling of HIV intact and defective
98 DNA decay.

99 Here, leveraging >500 longitudinal blood samples, we developed a novel mathematical
100 model of reservoir decay among 67 participants from the UCSF Treat Acute HIV cohort initiating
101 ART <100 days of HIV infection.⁴¹ We fit various mono-, bi-, and triphasic decay curves for both

102 HIV “intact” (infected cells harboring intact viral sequences able to produce infectious virions)
103 and “defective” (the majority of the HIV reservoir but incapable of producing infectious virions)
104 DNA, and we observed biphasic decay patterns for both measures. Furthermore, both HIV
105 intact and defective DNA decay rates were significantly faster among PWH with known clinical
106 factors associated with enhanced host viral control: higher initial CD4+ T cell count, earlier
107 initiation of ART, and lower pre-ART viral loads.^{23,24,34,42,43} As further validation of our
108 mathematical modeling approach, we also fit decay models for plasma HIV RNA (“viral load”
109 measured at each study visit using a standard clinical assay with limit of detection < 40
110 copies/mL). We observed a triphasic decay of plasma HIV RNA, similar to prior reports among
111 PWH initiating ART.^{3,4,40} Our data are the first to our knowledge to describe a predictive
112 mathematical model quantifying decay rates of HIV intact and defective DNA during acute
113 treated HIV.

114

115 **RESULTS**

116 **Characteristics of study participants**

117 A total of 67 adults (83% of those screened) with a new diagnosis of acute HIV (<100
118 days between HIV infection to ART initiation date) were included in the study (**Table 1**,
119 **Supplementary Fig. 1**).⁴⁴ All 67 participants completed monthly follow-up visits in the study for
120 the full 24 weeks. A large proportion (65.7%) of participants were co-enrolled in our longitudinal
121 UCSF SCOPE HIV cohort and remained in study beyond 24 weeks, with study visits
122 approximately every 3-4 months. The median follow-up for our cohort was 0.81 (interquartile
123 range = 0.47-1.66) years. We calculated the estimated date of detected infection (EDDI) for
124 each participant using an algorithm^{45,46} successfully applied to other acute HIV cohorts^{38,39}
125 (**Supplementary Fig. 2**). We also estimated Fiebig stage^{47,48} for each participant, an older but
126 often cited method for staging recency of HIV infection (**Fig. 1**). Consistent with our San
127 Francisco-based study population, participants were mostly male (97%) and reflected local and

128 national racial/ethnic trends of higher incident acute HIV in these populations (**Fig. 1**).⁴⁹
129 Baseline study visit HIV-1 antigen/antibody (Architect) and HIV-1 antibody (Geenius) testing
130 demonstrated 27% and 28% false negative/indeterminate rates (**Supplementary Fig. 3**),
131 respectively, consistent with our San Francisco Department of Public Health (SFDPH) reported
132 estimates for new acute HIV diagnoses.⁵⁰ Genotype data (Monogram) were available for a
133 subset of 57 participants; 77% had wild-type HIV, 9% had M184V/I mutations (all were reported
134 among participants citing prior and/or current pre-exposure prophylaxis [PrEP] use), and 14%
135 had evidence of possible partner-transmitted resistance mutations (based on referral of newly
136 diagnosed partners within our cohort and/or SFDPH partner tracing⁵⁰).

137 Our cohort also reflected a high proportion of self-reported prior PrEP use (42% ever
138 use, 20% use in the past 10 days), reflecting San Francisco's early and widespread adoption of
139 PrEP.⁵⁰ All PrEP reported in this study was oral PrEP with tenofovir disoproxil
140 fumarate/emtricitabine (TDF/FTC), as this was the only form clinically available during the study
141 period. Among individuals reporting overlapping PrEP use within 10 days of their EDDI, six
142 participants had probable HIV acquisition while on PrEP (median baseline log₁₀HIV RNA = 2.2
143 copies/mL, ~3 log₁₀ lower than those not reporting PrEP overlap) (**Table 1, Supplementary Fig.**
144 **4**), including one participant⁵¹ who may have acquired HIV in the setting of therapeutic PrEP
145 concentrations (confirmed by plasma and hair ART concentrations).

146

147 **Rapid biphasic decay of HIV intact and defective DNA**

148 Overall, after fitting various mono-, bi-, and triphasic decay curves using semiparametric
149 generalized additive models, we found that a biphasic decay pattern with an inflection point (τ) =
150 week 5 best fit the data for HIV intact and defective DNA (**Figs. 2-3, Supplementary Fig. 5**).
151 Validation of these models against the observed data showed good model performance (**Fig. 4,**
152 **Supplementary Figs. 6-7**) and that HIV intact and defective DNA decay patterns significantly

153 predicted faster decay rates (**Figs. 5-6**) for participants with known clinical factors associated
154 with smaller HIV reservoir size.^{23,24,34,42,43}

155 First, we modeled HIV intact and defective DNA using a linear effect of time on ART
156 (which assumes a constant rate of change regardless of the duration of viral suppression).
157 However, since we observed evidence of nonlinearity, we fit nonlinear generalized additive
158 models to better estimate HIV intact and defective DNA decay patterns. For all models, we
159 tested clinical factors of age, pre-ART CD4+ T cell count, pre-ART viral load, and timing of ART
160 initiation for inclusion as potential covariates. We found that both HIV intact and effective DNA
161 were well described by a biphasic model, comparing Akaike information criteria (AIC) (**Fig. 2a**)
162 and thus was chosen over a triphasic model since comparing the minimum predicted mean
163 absolute error (MAE) using leave-one-out cross-validation and/or the minimum predicted mean
164 squared error (MSE) (**Fig. 2b**), suggested similar inflection points. For HIV intact DNA, the first
165 and second inflection points were similar, suggesting that a single inflection point – i.e., a
166 biphasic model – adequately described the data, and for HIV defective DNA, since the first
167 inflection point was close to zero, this again suggested that a biphasic model well described the
168 data. We then further determined that the inflection point of $\tau = 5$ weeks, after comparing MAEs
169 and MSEs, was optimal for both HIV intact and defective DNA (**Fig. 3, Supplementary Fig. 5**).
170 Since we found that several key clinical factors (previously associated with HIV reservoir size
171 initiation^{23,24,34,42,43}) were strongly associated with HIV DNA decay rates (**Figs. 5-6**), all final
172 models included terms for initial CD4+ T cell count, pre-ART viral load, and timing of ART
173 initiation.

174 Our final biphasic decay model of HIV intact DNA demonstrated a rapid $t_{1/2} \sim 2.83$ (95%CI
175 = 2.39-3.27) weeks for the first ~ 5 weeks of AR, followed by a slower second decay phase with
176 a $t_{1/2} \sim 15.4$ (95%CI = 12.0-21.9) weeks (**Supplementary Table 1**). HIV defective DNA had a
177 similar pattern, with an initial rapid decay ($t_{1/2} \sim 1.36$, 95%CI = 1.17-1.55 weeks), followed by a
178 slower decay, but the change in decay was not statistically significantly given the large

179 variability in HIV defective DNA during this second phase (**Fig. 4**). Interestingly, we observed a
180 significantly faster decay of HIV defective vs. intact DNA during the first phase ($p < 1e-16$) (**Fig.**
181 **4**). While the reasons for this are unclear, given the frequency of our sampling at these acute
182 HIV timepoints, our observation may potentially be due to (1) a true biological phenomenon
183 uniquely captured by our frequent early sampling and/or (2) reflect unique properties of the
184 IPDA (see **Discussion**).

185 Our final models also demonstrated significantly faster decay rates with clinical factors
186 associated with smaller reservoir size (**Figs. 5-6**). For example, our models estimated that for
187 HIV intact DNA, for each week earlier that ART was initiated, the $t_{1/2}$ was predicted to be
188 reduced by ~ 0.0827 (95%CI = 0.0203-0.145) and by ~ 1.08 (95%CI = 0.316-1.84) during the
189 second phase (**Supplementary Table 3**). Similarly, our models predicted that higher initial
190 CD4+ T count and lower pre-ART HIV RNA predicted significantly faster HIV intact and
191 defective decay rates (**Supplementary Table 4**). Further validation using fitted spline models
192 again demonstrated that higher initial CD4+ T count and lower pre-ART HIV RNA predicted
193 faster HIV intact and defective DNA decay rates (**Supplementary Fig. 10**). For example, a
194 participant with an initial CD4+ T cell count of 900 cells/mm³ was predicted to have ~ 10 times
195 faster decay of HIV intact DNA than a participant with an initial CD4+ T cell count of 300
196 cells/mm³. Similar patterns were observed for HIV defective DNA, but the fitted splines were
197 less linear.

198 While we were unable to perform adjusted analyses for other important clinical factors such
199 as gender and race/ethnicity given the small sample sizes in our study (**Table 1**), we did
200 perform sensitivity analyses focusing on the small number of cisgender and transgender
201 women, as well as the small numbers of PWH reporting PrEP use within 10 days of HIV
202 diagnosis. These analyses demonstrated that results were overall relatively unchanged and that
203 these participants did not necessarily fall in the lower range of reservoir measurements
204 (**Supplementary Fig. 8**). Furthermore, to ensure that the selected inflection point of $\tau = 5$ weeks

205 was not influenced by potential outlier data, we performed three different sensitivity analyses
206 excluding participants for whom HIV reservoir measures might fall on the higher and/or lower
207 range of values: (1) individuals reporting prior PrEP use within 10 days of HIV infection, (2)
208 participants with plasma viral load “blips” (defined as a one-time viral load >1000 copies/mL or
209 two consecutive viral loads >100 copies/mL between weeks 0-24), and (3) participants with
210 sudden increases in HIV intact DNA (defined as >50% increase between two consecutive
211 measurements during weeks 0-24). These sensitivity analyses demonstrated that $\tau = 5$ weeks
212 remained a reasonable choice for the model’s inflection point (**Supplementary Fig. 9**) and that
213 the estimates were overall unchanged after exclusion (**Supplementary Table 2**).

214

215 **Triphasic decay of plasma HIV RNA**

216 As further validation of our mathematical modeling approach, we also fit decay models
217 for plasma HIV RNA. Plasma HIV RNA (“viral load”) was measured at each study visit using a
218 standard clinical assay (Abbott Real Time PCR assay, limit of detection < 40 copies/mL). We
219 again fit various mono-, bi-, and triphasic models, and a triphasic decay model best fit these
220 data with inflection points at 0.5 and 4 weeks (**Supplementary Fig. 11**). Our findings are
221 consistent with prior published work describing triphasic decay of plasma HIV RNA in treatment
222 naïve PWH initiating integrase inhibitor-based therapy.⁵² Our final adjusted models predicted a
223 rapid initial decay ($t_{1/2} \sim 0.659$, 95% CI = 0.541-0.778 days), a second decay ($t_{1/2} \sim 4.93$, 95% CI
224 = 3.98-5.89 days), with no significant decay during the third phase (**Supplementary Table 5**),
225 closely mirroring prior reported estimates describing a $t_{1/2} = 1.14, 9.19, \text{ and } 340$ days,
226 respectively.⁵² As expected, we observed that the majority of our cohort had undetectable
227 plasma viremia by a median of 4.14 weeks, consistent with viral suppression rates among
228 treatment naïve PWH initiating integrase inhibitor-based ART.^{53,54} Similar to our approach used
229 for our HIV DNA decay models, we validated our final triphasic plasma HIV RNA decay model
230 by comparing predicted vs. observed values and found that the model produced unbiased

231 estimates across a range of plasma HIV RNA values (**Supplementary Fig. 12**). We again found
232 that known clinical factors associated with reservoir size –e.g., initial CD4+ T cell count and
233 earlier timing of ART initiation –were also associated with accelerated decay rates
234 (**Supplementary Figs. 13-15**).

235

236 **DISCUSSION**

237 Leveraging >500 longitudinal blood samples from the UCSF Treat Acute HIV cohort, we
238 performed mathematical modeling and demonstrated a rapid biphasic decay of HIV intact and
239 defective DNA. Our estimates for HIV intact DNA decay were significantly faster (~5-fold)
240 compared to prior estimates from chronic treated³ PWH initiating ART. Furthermore, clinical
241 factors associated with smaller HIV reservoir sizes (e.g., earlier timing of ART initiation, higher
242 initial CD4+ T cell count, and lower pre-ART viral load) predicted faster decay rates of both HIV
243 intact and defective DNA. We further validated our modelling approach by fitting plasma HIV
244 RNA decay rates, and we observed a triphasic decay pattern, consistent with prior estimates.⁵²
245 Our mathematical modeling approach may serve as a meaningful way to predict expected
246 decay rates after ART initiation and the potential impact of clinical factors that may differ when
247 comparing across global HIV cohorts that may also have different host genetics, HIV-1
248 subtypes, etc. This approach may also help inform the design of future HIV cure trials, e.g., to
249 predict optimal timeframes during which an intervention may have the greatest impact on
250 accelerating reservoir decay and/or limiting reservoir establishment.

251 Our findings compare to several key prior modeling studies of HIV reservoir decay,^{3,55-58}
252 all of which fit mostly unadjusted fully parameterized mixed effects models but still lend support
253 to our findings. For example, we observed an initial rapid HIV intact DNA decay rate of $t_{1/2}$ of
254 ~2.83 weeks (~0.71 months), followed by a slower second phase with a $t_{1/2}$ ~15.4 weeks (~3.9
255 months). Strikingly, this first phase decay estimate is nearly identical to prior reports in chronic
256 treated PWH initiating ART ($t_{1/2} = 0.43$ months),³ but our estimates for the second phase of

257 decay were ~5-fold faster than estimates from this other study ($t_{1/2} = 19$ months), well below
258 their confidence limits (8.23-43.7 months).³ Our faster rate of HIV intact DNA decay during this
259 second phase are unclear but may potentially be due to true biological differences (e.g., less
260 exhausted immune cells compared to chronic treated PWH^{59,60}) or reflect greater precision in
261 estimating decay rates from our frequent sampling (every 2-4 weeks). The initial rapid decay of
262 HIV-infected cells after ART initiation is thought to be largely due to clearance of free virions and
263 death of productively infected cells.^{3,4,52,61,62} We estimated similar first phase decay rates as
264 those previously reported in chronic treated PWH initiating ART,³ suggesting that death of
265 productively infected cells, regardless of timing of ART initiation, may indeed be driving the first
266 phase decay estimates. Furthermore, plasma (cell-free) HIV RNA correlates with the frequency
267 of productively infected CD4+ T cells;⁶³ our plasma HIV RNA decay estimates provide further
268 support as these estimates are again consistent with prior reported clearance rates of
269 productively infected CD4+ T cells ($t_{1/2} \sim 0.7$ days).⁶⁴ Meanwhile, the second phase of reservoir
270 decay after ART initiation is thought to represent a “contraction phase” when activated cells
271 transition from an effector to a memory phenotype with ART-mediated antigen reduction.⁶⁵⁻⁶⁷
272 This second phase is thought to be largely driven by death of longer-lived memory cells.^{68,69}
273 Indeed, if we extrapolate the second phase of our HIV intact DNA model, we estimate that PWH
274 who delay ART initiation to ~56 weeks after HIV infection have a predicted $t_{1/2}$ that is
275 comparable to the (slower) second phase decay reported in chronic treated PWH.³ Our data
276 suggests that – especially during this second phase of decay – that curative interventions given
277 during this critical window of time may have the potential to significantly reduce the
278 establishment of these long-lived memory cells.

279 Our data are also consistent with findings from two prior acute HIV cohorts^{38,58} that did
280 not measure IPDA (HIV intact and defective DNA) but did measure HIV total, integrated DNA,
281 and 2-LTR DNA by real-time PCR⁷⁰ and also performed the quantitative viral outgrowth
282 (QVOA^{25,68,71}) and multiply spliced tat/rev (TILDA⁷²) assays. One of these studies by Massanella

283 and colleagues performed mathematical modeling and also demonstrated biphasic decays of
284 HIV total, integrated, and 2-LTR DNA, with a similar inflection point (6 weeks).⁵⁸ While they were
285 unable to report decay models for QVOA or TILDA (likely due to the low frequency of HIV-
286 infected cells despite the large number of input cells,^{73,74} which may have precluded more
287 complex decay modeling), their estimates for HIV total, integrated, and 2-LTR decay rates
288 closely compare to our estimates for defective DNA. The population of HIV-infected cells
289 generally falls into three broad categories: (1) truly “intact” proviruses, (2) “partially defective”
290 proviruses that can produce defective HIV RNA/proteins, which, despite being unable to
291 produce virus, can still lead to immunogenic/cytopathic effects,⁷⁵ and (3) truly “inert” proviruses
292 that express no HIV RNA or proteins. While the assays in this other study did not specifically
293 discriminate intact from defective viral sequences, since the majority of the HIV reservoir
294 consists of defective provirus⁷³ and since the majority of infected cells in acute PWH consist of
295 these highly unstable unintegrated linear HIV DNA (with an estimated half-life of ~2 days),⁷⁶ the
296 overlap in our modeling results may suggest an overlap in the population of HIV-infected cells
297 captured by our respective assays.

298 Finally, it is important to note that the decay rates described here are likely
299 complementary to, but not the same as, decay rates described in several long-term ART
300 studies.^{34-37,71,77} First, these long-term ART studies (in chronic treated PWH) did not sample
301 participants at the time of ART initiation and had less frequent sampling over longer periods of
302 ART suppression.^{34-36,57} Overall, these studies described a biphasic decay (inflection point ~7
303 years of ART) with a $t_{1/2}$ ~44 months for HIV intact DNA^{71,77} and found that HIV intact DNA
304 decayed faster than defective DNA, presumably due to preferential clearance of intact, or
305 “replication-competent”, provirus during long-term ART.^{34-36,57,78,79} However, HIV intact DNA
306 decay rates have also been shown to plateau or even an increase in some individuals during
307 prolonged ART.^{36,57} Our biphasic model identified a somewhat surprising finding that HIV
308 defective DNA decayed faster than HIV intact DNA during the first phase. The reasons for this

309 are unclear but may reflect true biological phenomena uniquely captured by our frequent early
310 sampling and/or unique properties of the IPDA. Since the majority of the HIV reservoir consists
311 of defective provirus,⁷³ estimates of HIV total, integrated, and 2-LTR DNA decay rates from the
312 study by Massanella et. al., ($t_{1/2} = 14.5, 14.1, \text{ and } 30.5$ days, respectively⁵⁸) are largely
313 consistent with our estimates of defective DNA decay rates ($t_{1/2} = 9.5$ days) during the first phase
314 of decay, suggesting a potential true biological phenomena that warrants further study.
315 Alternatively, a second possibility is that our observations reflect some misclassification of HIV
316 “intact” provirus (i.e., since the IPDA targets just two regions of the HIV genome to define
317 “defective” provirus⁸⁰). However, Reeves and colleagues recently performed detailed validation
318 experiments (e.g., using quantitative viral outgrowth assay and near full-length sequencing) and
319 showed that the rate of misclassification is <5% with the IPDA,⁵⁵ suggesting that this degree of
320 misclassification alone would be unlikely to fully explain our findings.

321 Our study has several limitations that deserve mention. While we leveraged several
322 hundred longitudinal blood samples from acute treated PWH, we did not model the HIV tissue
323 reservoir; our tissue studies are currently underway but will be limited in the number of
324 longitudinal timepoints to perform similar detailed modeling. Since the peripheral HIV reservoir
325 largely reflects proviruses originating from the tissue reservoir,^{38,81-83} tissue reservoir decay
326 estimates in ours as well as other studies should be modeled in parallel with the more frequently
327 sampled peripheral reservoir decay estimates in future work. We performed IPDA, which, while
328 highly scalable for a large number of samples, less accurately quantifies the replication-
329 competent reservoir compared to near-full length proviral sequencing or QVOA. Nonetheless,
330 HIV intact DNA measured by IPDA closely reflect results from these other assays, even
331 considering the known enrichment of integrated forms of HIV DNA observed in acute PWH.³⁸ As
332 with all molecular assays for HIV, certain polymorphisms at primer or probe binding sites can
333 impact IPDA assay performance. We observed IPDA signal failure for 6 participants (8.9%) – a
334 rate consistent reports from large HIV cohorts from North America and Europe where subtype B

335 predominates (6-7%).^{34,84} We also did not measure changes in clonal landscape (e.g., HIV
336 integration). The clonal landscape at the time of acute HIV is extremely diverse, and we
337 hypothesize that this effect is more likely to have greater higher impact after longer duration of
338 ART suppression. Future models should include these parameters to formally test this
339 hypothesis. Finally, there are few highly characterized acute HIV cohorts to date, and each
340 study possesses unique host and viral characteristics making direct cross-cohort comparisons
341 challenging. Our study included mostly men who have sex with men and HIV-1 subtype B. It will
342 be critical to validate our HIV reservoir decay models in global populations with distinct host
343 genetic ancestry, HIV-1 subtypes, and clinical features to facilitate cross-cohort comparisons
344 and inform future HIV cure trial design and interpretation.

345 The long-lived latent reservoir is a key defining target for HIV cure, but how and where
346 these cells then become “the long-lasting latent reservoir” remains unclear. Even in reservoir
347 decay studies analyzing data out to 20 years of ART suppression, decay patterns are not
348 broadly generalizable.^{36,57} Thus, there is a critical need for a scalable approach to broaden our
349 understanding of HIV reservoir decay patterns across a global population of PWH, ideally
350 aligning study designs and assays and performing meta-analyses, including how key clinical
351 factors such as the timing of ART initiation, initial CD4+ T cell count, and pre-ART viral load
352 influence decay rates.

353

354 **METHODS**

355 **Study participants**

356 Individuals with newly diagnosed acute (<100 days) from HIV infection were enrolled in
357 the UCSF Treat Acute HIV cohort between December 1, 2015 to November 30, 2020 and co-
358 enrolled in the UCSF SCOPE HIV cohort, an ongoing longitudinal study of over 2,500 PWH.
359 Eligible participants were provided same-day ART initiation with tenofovir/emtricitabine

360 (TDF/FTC, then TAF/FTC once available in 2016) + dolutegravir (DTG) and linked to clinical
361 care.⁵⁰ Individuals reporting concomitant PrEP use (<100 days from any potential exposure to
362 HIV by history and/or clinical test results) were also started on darunavir+ritonavir (DRV/r) as a
363 fourth drug, which was continued until confirmation of baseline HIV genotyping test results
364 (Monogram Biosciences, South San Francisco, CA, U.S.A.). Additional ART changes necessary
365 for clinical care (e.g., laboratory abnormalities, drug-drug interactions, and/or participant
366 preference) were honored and adjusted during the period of study. Participants signed a release
367 of information which allowed clinical data extraction to determine prior HIV negative test results
368 from the SFDPH, as well as additional HIV test results.

369 Study participants were seen for monthly study visits for the first 24 weeks (including an
370 additional week 2 visit to confirm HIV test results from baseline visit) and then every 3-4 months
371 thereafter. Inclusion criteria for the study were prior HIV negative testing within the last 90 days,
372 laboratory-confirmed HIV-1 infection by antibody/antigen and/or plasma HIV RNA assay, and
373 willingness to be participate in the study for at least 24 weeks. Participants with severe renal or
374 hepatic impairment, concurrent treatment with immunomodulatory drugs, or exposure to any
375 immunomodulatory drugs in the preceding 90 days prior to study entry, pregnant or
376 breastfeeding women, or participants unwilling to agree to the use a double-barrier method of
377 contraception throughout the study period, were excluded. For each study participant, the
378 estimated date of detected HIV infection (EDDI) was calculated using the Infection Dating Tool
379 (<https://tools.incidence-estimation.org/idt/>).⁴⁵ At each visit, detailed interviews included questions
380 regarding current medications, medication adherence, intercurrent illnesses, and
381 hospitalizations were performed. In addition, peripheral blood sampling at each visit was
382 performed to measure plasma HIV RNA (Abbott Real Time PCR assay, limit of detection <40
383 copies/mL), CD4+ T cell count, and clinical labs (complete blood count, metabolic panel). All

384 participants provided written informed consent, and the institutional review board of UCSF
385 approved the research.

386

387 **HIV reservoir quantification**

388 The frequencies of HIV intact and defective (3' and 5') DNA were quantified using the
389 intact proviral DNA assay (IPDA).⁸⁵ CD4+ T cells were isolated from cryopreserved PBMCs
390 (EasySep Human CD4+ T cell Enrichment Kit, Stemcell Technologies), with cell count, viability,
391 and purity assessed by flow cytometry. Negatively selected CD4+ T cells were recovered
392 (median cells = 2×10^6 with median viability = 97%) and genomic DNA extracted using the
393 QIAamp DNA Mini Kit (Qiagen). DNA concentration and quality were determined by fluorometry
394 (Qubit dsDNA BR Assay Kit, Thermo Fisher Scientific) and ultraviolet-visible (UV/VIS)
395 spectrophotometry (QIAxpert, Qiagen). The frequency of intact provirus was determined using
396 two multiplex digital droplet polymerase chain reaction (ddPCR) assays performed in parallel:
397 (1) the HIV-1 Proviral Discrimination reaction which distinguishes intact from defective provirus
398 via two strategically placed amplicons in HIV psi and RRE regions as well as a hypermutation
399 discrimination probe, and (2) the Copy Reference/Shearing reaction, which quantifies DNA
400 shearing and input diploid cell equivalents using the human *RPP30* gene.⁸⁵ All ddPCR reactions
401 were assembled via automated liquid handles to maximize reproducibility and analyzed using
402 the BioRad QX200 AutoDG Digital Droplet PCR system (BioRad). Up to 700 ng of genomic
403 DNA were analyzed per reaction, and final input DNA concentrations were dependent upon
404 recovered DNA concentrations. Samples were batch processed and analyzed, including
405 negative controls from uninfected donors and J-Lat full-length clone 6.3 (E. Verdin, Gladstone
406 Institutes and UCSF, San Francisco, CA, USA) cells as positive controls. Across >500 IPDA
407 measurements, we interrogated a median of 4.8×10^5 CD4+ T cell genomes per assay and
408 observed a median DNA shearing index (DSI) of 0.40.

409

410 **Statistical Methods**

411 We developed a novel semiparametric biphasic decay model to estimate the HIV DNA
412 reservoir size over time in \log_{10} copies per 10^6 CD4+ T cells as

$$\log_{10}(I_{it}) \sim f_1(T_{it}; \tau, \beta_1, \beta_2) + E_i \cdot f_1(T_{it}; \tau, \beta_3, \beta_4) + f_2(C_i) + f_3(V_i) + \mu_i, \#(1)$$

413 where in I_{it} represents either the HIV intact or defective DNA reservoir size, of the i -th
414 participant at t -th visit. The number of weeks since ART initiation is denoted T_{it} . The model
415 additionally accounts for baseline clinical information defined as the initial CD4+ T cell count, C_i ,
416 pre-ART viral load, V_i , and the estimated time between HIV infection and ART initiation, E_i . The
417 delay in ART initiation was centered to have a mean of zero prior to analysis; this offset was
418 approximately 60 days in our cohort. Participant-level random effects, μ_i , are also included.
419 Building on existing models,^{3,57} we parameterized the decay as a continuous, linear spline with a
420 single knot at τ : $f_1(T_{it}; \tau, \beta_1, \beta_2) = \beta_1 \cdot \min\{T_{it}, \tau\} + \beta_2 \cdot \max\{T_{it} - \tau, 0\}$. Under this
421 parameterization, β_1 and β_2 represent the decay rate before and after τ , respectively. For
422 triphasic models, the decay was modeled as a continuous, linear spline with knots at τ_1 and τ_2 .
423 For monophasic models, the decay was modeled as a linear function of time. The same spline
424 parameterization and inflection point(s) were used to model the time on ART and interaction
425 between time on ART and delay in ART initiation; different slopes were estimated for these two
426 terms. Cubic splines were used for both $f_2(C_i)$ and $f_3(V_i)$. After fixing the inflection point(s),
427 model estimation was performed using the `mgcv` (v1.9-1) package in R (4.3.1). A two-sided
428 Welch's t-test was used to compare decay rate estimates across models.

429 Regardless of the HIV measure (intact DNA, defective DNA, or plasma RNA), the
430 inflection point, τ , was estimated by minimizing the model's mean absolute prediction error.
431 Candidate τ values were tested iteratively (from 0 weeks to 24 weeks) and the mean absolute
432 errors (MAEs) were estimated using leave-one-out cross-validation:

$$MAE(\tau) = \sum_{i,t} \left| \log_{10}(I_{it}) - \log_{10}(\hat{I}_{it}^{(-i)}) \right|, \#(2)$$

433 where $\hat{I}_{it}^{(-i)}$ reflected the predicted HIV DNA counts for participant i at time t using the model fit
 434 for each participant (excluding participant i). Inflection points for the triphasic model were
 435 estimated similarly. We then compared the fit of various models using Akaike information criteria
 436 (AIC).

437 To facilitate the interpretability of our results and to allow direct comparison with prior
 438 reports,^{3,52,58} we estimated decay half-lives, and their confidence intervals for each phase of
 439 decay, using the multivariate delta method.⁸⁶ For example, the half-life in the first decay phase,
 440 from model (1), was calculated as

$$t_{1/2}(E_i) = -\frac{0.25 \log_{10}(2)}{\beta_1 + \beta_2 E_i} = -\frac{0.25 \log_{10}(2)}{\beta_1} + \frac{0.25 \log_{10}(2) \beta_2 E_i}{\beta_1^2} + O(E_i^2), \#(3)$$

441 where the second equality reflected the degree-one Taylor series about $E_i = 0$. We centered E_i
 442 prior to model estimation to justify the degree-one Taylor series approximation of half-life. Thus,
 443 we estimated the baseline $t_{1/2}$ as $g_1(\beta_1, \beta_2) = -0.25 \log_{10}(2) / \beta_1$ and the adjusted $t_{1/2}$ (for each
 444 week delay in ART initiation) as $g_2(\beta_1, \beta_2) = 0.25 \log_{10}(2) \beta_2 / \beta_1^2$. Finally, we included our
 445 estimated model parameters into the delta method to obtain half-life estimates:

$$\sqrt{n} \left(\begin{bmatrix} g_1(\hat{\beta}_1, \hat{\beta}_2) \\ g_2(\hat{\beta}_1, \hat{\beta}_2) \end{bmatrix} - \begin{bmatrix} g_1(\beta_1, \beta_2) \\ g_2(\beta_1, \beta_2) \end{bmatrix} \right) \xrightarrow{d} N \left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, J \Sigma J^T \right) \#(4)$$

$$J = 0.25 \log_{10}(2) \begin{bmatrix} \frac{1}{\beta_1^2} & 0 \\ -2 \frac{\beta_2}{\beta_1^2} & \frac{1}{\beta_1^2} \end{bmatrix}, \#(5)$$

446 where Σ reflected the covariance between β_1 and β_2 , and J was the Jacobian matrix of $g(\beta_1, \beta_2)$.
 447 For further interpretability, we calculated the percent decay/week (prior to τ) using the
 448 transformation $h(\beta_1) = -100(2^{\beta_1} - 1)$. Similar calculations were performed for the second
 449 decay phase using β_3 and β_4 instead of β_1 and β_2 .

450 We performed further validation of our proposed HIV DNA (intact, defective) and HIV
451 RNA (plasma) decay models against known clinical factors associated with HIV reservoir
452 size.^{23,24,34,42,43} Focusing on the clinical covariates of (i) initial CD4+ T cell count, (ii) pre-ART
453 viral load, and (iii) timing of ART initiation (days from HIV infection to ART start date), we
454 performed bootstrapping predictions by resampling and generating 300 new participants. The
455 final HIV decay models (intact DNA, defective DNA, plasma RNA) were used to predict decay
456 patterns for each resampled (bootstrapped) participant. For data visualization, we partitioned
457 the resampled data into tertiles to demonstrate average predicted decay patterns by tertiles of
458 each clinical predictor.


Table 1. UCSF Treat Acute HIV Study Population. Medians (with interquartile ranges) or frequencies (with percentages) are shown.

	N = 67
Timing of ART initiation (days from date of detected HIV infection to ART start date)	31.0 (22.0 – 88.5)
Initial CD4+ T-cell count (cells/mm ³)	505 (350 – 670)
Pre-ART plasma HIV RNA (log ₁₀ copies)	4.85 (3.69 – 5.65)
Age	30.0 (25.5 – 38.0)
Gender (self-reported)	
Male	65 (97.0%)
Cisgender Female	1 (1.50%)
Transgender Female	1 (1.50%)
Race/ethnicity (self-reported)	
White	22 (32.8%)
Latinx	20 (29.9%)
Asian	14 (20.9%)
Black	10 (14.9%)
Other	1 (1.5%)
Prior pre-exposure prophylaxis (PrEP)	29 (43.3%)
HIV acquisition/PrEP overlap <10 days	15 (22.4%)
PrEP initiated but already acquired HIV	8 (11.9%)
HIV acquired on PrEP ^a	6 (9.0%)
Referral HIV testing sites	
San Francisco Department Public Health (%)	28 (41.8%)
Community-Based Organization (%)	29 (43.2%)
Private Health Clinics (%)	10 (14.9%)
Unstably housed	2 (3.0%)

^a For participants with HIV acquired on PrEP: median baseline plasma log₁₀HIV RNA was 2.2 copies/mL.

Fig. 1: The distribution of study participants in the UCSF Treat Acute HIV cohort. A total of 67 participants met inclusion criteria for acute HIV, defined as <100 days since the estimated date of detected HIV infection (EDDI) using the Infection Dating Tool (<https://tools.incidence-estimation.org/idt/>); these estimates were then used to estimate acute HIV Fiebig stages (a).^{47,48} The majority of the cohort was of non-White self-reported race/ethnicity, consistent with national trends for people incident acute HIV (b).⁴⁹

a.



b.




Fig. 2: Semiparametric monophasic, biphasic, and triphasic generalized additive models of HIV reservoir decay during weeks 0-24. We performed bootstrapping to estimate the Akaike information criteria (AIC) value and 95% confidence intervals and compared monophasic, biphasic, and triphasic models for both HIV intact (left panels) and defective (right panels) DNA assays (a). Using the triphasic models for HIV intact (left panel) and defective (right panel) DNA, we then determined the optimal inflection point(s), τ , by minimizing the predicted mean absolute error (MAE; top panels) using leave-one-out cross-validation or the predicted mean squared error (MSE; bottom panels) (b). Red dots denote the optimal inflection point(s), τ , for each model and prediction loss metric. For HIV intact DNA, the first (x-axis) and second (y-axis) inflection points were relatively similar, suggesting that a single inflection point – i.e., a biphasic model – adequately described the data. For HIV defective DNA, the first inflection point (x-axis) was close to zero, this again suggested that a biphasic model reasonably described the data.

a.

HIV Reservoir	Monophasic (95% CI)	Biphasic (95% CI)	Triphasic (95% CI)
Intact DNA	886 (722, 1023)	797 (595, 968)	796 (597, 965)
Defective DNA	1426 (1344, 1504)	1268 (1183, 1343)	1272 (1188, 1348)

b.





Fig. 3 Determination of optimal inflection points for HIV intact and defective DNA biphasic decay models. Using the biphasic models for HIV intact (left panel) and defective (right panel) DNA, we then determined the optimal inflection point(s), τ , by minimizing the predicted mean absolute error (MAE; top panels) using leave-one-out cross-validation or the predicted mean squared error (MSE; bottom panels) (b). An inflection point of $\tau = 5$ weeks (vertical dashed line) best fit decay patterns for both HIV intact (left panels) and defective (right panels) DNA. Red dots denote the best τ for each model and prediction error metric.

a. HIV intact DNA



b. HIV defective DNA




Fig. 4 Predicted decay patterns of HIV intact and defective DNA during acute treated HIV from weeks 0-24. Decay patterns for observed (thin grey lines) HIV intact and total defective (a), as well as 3' and 5' defective (b) DNA closely fit with average model predictions (thick black lines). Sampling timepoints are labeled on the x-axis (including a week 2 study visit during which confirmatory HIV test results were disclosed). We estimated average predicted participant decay rates by taking the mean of (estimated time between HIV infection and ART initiation), (initial CD4+ T cell count), and (\log_{10} pre-ART plasma viral load) across participants from final models.






Fig. 5 HIV intact and defective DNA decay patterns were associated with known clinical factors associated with HIV reservoir size. The observed HIV DNA data are shown as thin grey lines for each participant, while the decay pattern for the model-predicted average participant is shown as the thick black lines. Biphasic decay patterns for HIV intact (left panel) and combined defective (3' plus 5', right panel) were faster among participants initiating ART earlier (<30 days vs. 30-100 days) (a), with higher initial CD4+ T cell counts (shown by tertiles) (b), and lower pre-ART viral load (shown by tertiles) (c).


a.



b.




c.




1 **Fig. 6 Predicted HIV intact and defective DNA decay rates, by tertiles of clinical factors**
2 **associated with HIV reservoir size.** We performed bootstrapping to estimate the average
3 predicted decay rates of HIV intact (left panels) and defective (right panels) DNA, stratified by
4 tertiles of known clinical factors associated with HIV reservoir size: timing of ART initiation (a),
5 initial CD4+ T cell count (b), and pre-ART viral load (c).


6 **a.**



8 **b.**



12 **c.**



13

14

15 REFERENCES

- 16 1 Chun, T. W. *et al.* Rebound of plasma viremia following cessation of antiretroviral
17 therapy despite profoundly low levels of HIV reservoir: implications for
18 eradication. *AIDS* **24**, 2803-2808 (2010).
19 <https://doi.org/10.1097/QAD.0b013e328340a239>
- 20 2 Hocqueloux, L. *et al.* Long-term immunovirologic control following antiretroviral
21 therapy interruption in patients treated at the time of primary HIV-1 infection.
22 *AIDS* **24**, 1598-1601 (2010). <https://doi.org/10.1097/qad.0b013e32833b61ba>
- 23 3 White, J. A. *et al.* Complex decay dynamics of HIV virions, intact and defective
24 proviruses, and 2LTR circles following initiation of antiretroviral therapy. *Proc Natl*
25 *Acad Sci U S A* **119** (2022). <https://doi.org/10.1073/pnas.2120326119>
- 26 4 Perelson, A. S. *et al.* Decay characteristics of HIV-1-infected compartments
27 during combination therapy. *Nature* **387**, 188-191 (1997).
28 <https://doi.org/10.1038/387188a0>
- 29 5 Kwon, K. J. & Siliciano, R. F. HIV persistence: clonal expansion of cells in the
30 latent reservoir. *J Clin Invest* **127**, 2536-2538 (2017).
31 <https://doi.org/10.1172/JCI95329>
- 32 6 Finzi, D. & Siliciano, R. F. Viral dynamics in HIV-1 infection. *Cell* **93**, 665-671
33 (1998). [https://doi.org/10.1016/s0092-8674\(00\)81427-0](https://doi.org/10.1016/s0092-8674(00)81427-0)
- 34 7 Chomont, N. *et al.* HIV reservoir size and persistence are driven by T cell survival
35 and homeostatic proliferation. *Nature medicine* **15**, 893-900 (2009).
36 <https://doi.org/10.1038/nm.1972>

- 37 8 Yukl, S. A. *et al.* Differences in HIV burden and immune activation within the gut
38 of HIV-positive patients receiving suppressive antiretroviral therapy. *The Journal*
39 *of infectious diseases* **202**, 1553-1561 (2010). <https://doi.org/10.1086/656722>
- 40 9 Archin, N. M. *et al.* Administration of vorinostat disrupts HIV-1 latency in patients
41 on antiretroviral therapy. *Nature* **487**, 482-485 (2012).
42 <https://doi.org/10.1038/nature11286>
- 43 10 Elliott, J. H. *et al.* Short-term administration of disulfiram for reversal of latent HIV
44 infection: a phase 2 dose-escalation study. *Lancet HIV* **2**, e520-529 (2015).
45 [https://doi.org/10.1016/S2352-3018\(15\)00226-X](https://doi.org/10.1016/S2352-3018(15)00226-X)
- 46 11 Rasmussen, T. A. *et al.* Panobinostat, a histone deacetylase inhibitor, for latent-
47 virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a
48 phase 1/2, single group, clinical trial. *Lancet HIV* **1**, e13-21 (2014).
49 [https://doi.org/10.1016/S2352-3018\(14\)70014-1](https://doi.org/10.1016/S2352-3018(14)70014-1)
- 50 12 Elliott, J. H. *et al.* Activation of HIV transcription with short-course vorinostat in
51 HIV-infected patients on suppressive antiretroviral therapy. *PLoS pathogens* **10**,
52 e1004473 (2014). <https://doi.org/10.1371/journal.ppat.1004473>
- 53 13 Gay, C. L. *et al.* Assessing the impact of AGS-004, a dendritic cell-based
54 immunotherapy, and vorinostat on persistent HIV-1 Infection. *Sci Rep* **10**, 5134
55 (2020). <https://doi.org/10.1038/s41598-020-61878-3>
- 56 14 Fidler, S. *et al.* Antiretroviral therapy alone versus antiretroviral therapy with a
57 kick and kill approach, on measures of the HIV reservoir in participants with
58 recent HIV infection (the RIVER trial): a phase 2, randomised trial. *Lancet* **395**,
59 888-898 (2020). [https://doi.org/10.1016/S0140-6736\(19\)32990-3](https://doi.org/10.1016/S0140-6736(19)32990-3)

- 60 15 Gutierrez, C. *et al.* Bryostatins for latent virus reactivation in HIV-infected
61 patients on antiretroviral therapy. *AIDS* **30**, 1385-1392 (2016).
62 <https://doi.org/10.1097/QAD.0000000000001064>
- 63 16 Vibholm, L. *et al.* Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts
64 Innate Immunity and Plasma Viremia in Individuals With Human
65 Immunodeficiency Virus Infection. *Clin Infect Dis* **64**, 1686-1695 (2017).
66 <https://doi.org/10.1093/cid/cix201>
- 67 17 Riddler, S. A. *et al.* Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune
68 Activation in Virally Suppressed Adults Living With Human Immunodeficiency
69 Virus-1. *Clin Infect Dis* **72**, e815-e824 (2021).
70 <https://doi.org/10.1093/cid/ciaa1534>
- 71 18 Elliott, J. H. *et al.* Short-term administration of disulfiram for reversal of latent HIV
72 infection: a phase 2 dose-escalation study. *Lancet HIV* **2**, e520-529 (2015).
73 [https://doi.org/10.1016/S2352-3018\(15\)00226-X](https://doi.org/10.1016/S2352-3018(15)00226-X)
- 74 19 Bar, K. J. *et al.* Effect of HIV Antibody VRC01 on Viral Rebound after Treatment
75 Interruption. *N Engl J Med* **375**, 2037-2050 (2016).
76 <https://doi.org/10.1056/NEJMoa1608243>
- 77 20 Gunst, J. D. *et al.* Early intervention with 3BNC117 and romidepsin at
78 antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized
79 trial. *Nat Med* **28**, 2424-2435 (2022). <https://doi.org/10.1038/s41591-022-02023-7>
- 80 21 Gunst, J. D. *et al.* in *Conference on Retroviruses and Opportunistic Infections*.

- 81 22 Namazi, G. *et al.* The Control of HIV After Antiretroviral Medication Pause
82 (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. *J*
83 *Infect Dis* **218**, 1954-1963 (2018). <https://doi.org/10.1093/infdis/jiy479>
- 84 23 Archin, N. M. *et al.* Immediate antiviral therapy appears to restrict resting CD4+
85 cell HIV-1 infection without accelerating the decay of latent infection. *Proc Natl*
86 *Acad Sci U S A* **109**, 9523-9528 (2012).
87 <https://doi.org/10.1073/pnas.1120248109>
- 88 24 Buzon, M. J. *et al.* Long-term antiretroviral treatment initiated at primary HIV-1
89 infection affects the size, composition, and decay kinetics of the reservoir of HIV-
90 1-infected CD4 T cells. *J Virol* **88**, 10056-10065 (2014).
91 <https://doi.org/10.1128/JVI.01046-14>
- 92 25 Chun, T. W. *et al.* Early establishment of a pool of latently infected, resting
93 CD4(+) T cells during primary HIV-1 infection. *Proc Natl Acad Sci U S A* **95**,
94 8869-8873 (1998). <https://doi.org/10.1073/pnas.95.15.8869>
- 95 26 Strain, M. C. *et al.* Effect of treatment, during primary infection, on establishment
96 and clearance of cellular reservoirs of HIV-1. *J Infect Dis* **191**, 1410-1418 (2005).
97 <https://doi.org/10.1086/428777>
- 98 27 Hocqueloux, L., Saez-Cirion, A. & Rouzioux, C. Immunovirologic control 24
99 months after interruption of antiretroviral therapy initiated close to HIV
100 seroconversion. *JAMA Intern Med* **173**, 475-476 (2013).
101 <https://doi.org/10.1001/jamainternmed.2013.2176>
- 102 28 Ananworanich, J. *et al.* Virological and immunological characteristics of HIV-
103 infected individuals at the earliest stage of infection. *J Virus Erad* **2**, 43-48 (2016).

- 104 29 Ananworanich, J. *et al.* Impact of multi-targeted antiretroviral treatment on gut T
105 cell depletion and HIV reservoir seeding during acute HIV infection. *PLoS One* **7**,
106 e33948 (2012). <https://doi.org/10.1371/journal.pone.0033948>
- 107 30 Deleage, C. *et al.* Impact of early cART in the gut during acute HIV infection. *JCI*
108 *Insight* **1** (2016). <https://doi.org/10.1172/jci.insight.87065>
- 109 31 Takata, H. *et al.* Long-term antiretroviral therapy initiated in acute HIV infection
110 prevents residual dysfunction of HIV-specific CD8(+) T cells. *EBioMedicine* **84**,
111 104253 (2022). <https://doi.org/10.1016/j.ebiom.2022.104253>
- 112 32 Oxenius, A. *et al.* Early highly active antiretroviral therapy for acute HIV-1
113 infection preserves immune function of CD8+ and CD4+ T lymphocytes. *Proc*
114 *Natl Acad Sci U S A* **97**, 3382-3387 (2000).
115 <https://doi.org/10.1073/pnas.97.7.3382>
- 116 33 Streeck, H. *et al.* Immunological and virological impact of highly active
117 antiretroviral therapy initiated during acute HIV-1 infection. *J Infect Dis* **194**, 734-
118 739 (2006). <https://doi.org/10.1086/503811>
- 119 34 Peluso, M. J. *et al.* Differential decay of intact and defective proviral DNA in HIV-
120 1-infected individuals on suppressive antiretroviral therapy. *JCI Insight* **5** (2020).
121 <https://doi.org/10.1172/jci.insight.132997>
- 122 35 Gandhi, R. T. *et al.* Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral
123 Therapy. *J Infect Dis* **223**, 225-233 (2021). <https://doi.org/10.1093/infdis/jiaa532>
- 124 36 Gandhi, R. T. *et al.* Varied Patterns of Decay of Intact Human Immunodeficiency
125 Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy. *J Infect Dis*
126 **227**, 1376-1380 (2023). <https://doi.org/10.1093/infdis/jiad039>

- 127 37 Antar, A. A. *et al.* Longitudinal study reveals HIV-1-infected CD4+ T cell
128 dynamics during long-term antiretroviral therapy. *J Clin Invest* **130**, 3543-3559
129 (2020). <https://doi.org/10.1172/JCI135953>
- 130 38 Leyre, L. *et al.* Abundant HIV-infected cells in blood and tissues are rapidly
131 cleared upon ART initiation during acute HIV infection. *Sci Transl Med* **12** (2020).
132 <https://doi.org/10.1126/scitranslmed.aav3491>
- 133 39 Massanella, M. *et al.* Long-term effects of early antiretroviral initiation on HIV
134 reservoir markers: a longitudinal analysis of the MERLIN clinical study. *Lancet*
135 *Microbe* **2**, e198-e209 (2021). [https://doi.org/10.1016/S2666-5247\(21\)00010-0](https://doi.org/10.1016/S2666-5247(21)00010-0)
- 136 40 De Clercq, J. *et al.* Longitudinal patterns of inflammatory mediators after acute
137 HIV infection correlate to intact and total reservoir. *Front Immunol* **14**, 1337316
138 (2023). <https://doi.org/10.3389/fimmu.2023.1337316>
- 139 41 Shi, L. *et al.* in *International AIDS Society Conference on HIV Science*.
- 140 42 Ananworanich, J. *et al.* HIV DNA Set Point is Rapidly Established in Acute HIV
141 Infection and Dramatically Reduced by Early ART. *EBioMedicine* **11**, 68-72
142 (2016). <https://doi.org/10.1016/j.ebiom.2016.07.024>
- 143 43 Crowell, T. A. *et al.* Virologic failure is uncommon after treatment initiation during
144 acute HIV infection. *AIDS* **30**, 1943-1950 (2016).
145 <https://doi.org/10.1097/QAD.0000000000001148>
- 146 44 Lee SA, H. T., Gandhi M, Coffey S, Harting H, Hoh R, Peluso MJ, Siegel D,
147 Crouch P, Scott H, Cohen SD, Sachdev D, Bacon O, Busch M, Pilcher C,
148 Buchbinder S, Havlir DV, Deeks SG. in *International AIDS Society Conference*.

- 149 45 Grebe, E. *et al.* Interpreting HIV diagnostic histories into infection time estimates:
150 analytical framework and online tool. *BMC Infect Dis* **19**, 894 (2019).
151 <https://doi.org/10.1186/s12879-019-4543-9>
- 152 46 Facente, S. N. *et al.* Estimated dates of detectable infection (EDDIs) as an
153 improvement upon Fiebig staging for HIV infection dating. *Epidemiol Infect* **148**,
154 e53 (2020). <https://doi.org/10.1017/S0950268820000503>
- 155 47 Fiebig, E. W. *et al.* Dynamics of HIV viremia and antibody seroconversion in
156 plasma donors: implications for diagnosis and staging of primary HIV infection.
157 *AIDS* **17**, 1871-1879 (2003).
158 <https://doi.org/10.1097/01.aids.0000076308.76477.b8>
- 159 48 Keele, B. F. *et al.* Identification and characterization of transmitted and early
160 founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A*
161 **105**, 7552-7557 (2008). <https://doi.org/10.1073/pnas.0802203105>
- 162 49 Prevention., C. f. D. C. a. HIV Surveillance Report.
163 <http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html>. Published May 2022.
164 Accessed Nov 2, 2023., (2020).
- 165 50 Buchbinder, S. P. & Havlir, D. V. Getting to Zero San Francisco: A Collective
166 Impact Approach. *J Acquir Immune Defic Syndr* **82 Suppl 3**, S176-S182 (2019).
167 <https://doi.org/10.1097/QAI.0000000000002200>
- 168 51 Cohen, S. E. *et al.* Acquisition of tenofovir-susceptible, emtricitabine-resistant
169 HIV despite high adherence to daily pre-exposure prophylaxis: a case report.
170 *Lancet HIV* (2018). [https://doi.org/10.1016/S2352-3018\(18\)30288-1](https://doi.org/10.1016/S2352-3018(18)30288-1)

- 171 52 Andrade, A. *et al.* Three distinct phases of HIV-1 RNA decay in treatment-naive
172 patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. *J Infect*
173 *Dis* **208**, 884-891 (2013). <https://doi.org/10.1093/infdis/jit272>
- 174 53 Raffi, F. *et al.* Once-daily dolutegravir versus twice-daily raltegravir in
175 antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results
176 from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis* **13**, 927-
177 935 (2013). [https://doi.org/10.1016/S1473-3099\(13\)70257-3](https://doi.org/10.1016/S1473-3099(13)70257-3)
- 178 54 Powderly, W. G. Integrase inhibitors in the treatment of HIV-1 infection. *J*
179 *Antimicrob Chemother* **65**, 2485-2488 (2010). <https://doi.org/10.1093/jac/dkq350>
- 180 55 Reeves, D. B. *et al.* Impact of misclassified defective proviruses on HIV reservoir
181 measurements. *Nat Commun* **14**, 4186 (2023). [https://doi.org/10.1038/s41467-](https://doi.org/10.1038/s41467-023-39837-z)
182 [023-39837-z](https://doi.org/10.1038/s41467-023-39837-z)
- 183 56 Reeves, D. B. *et al.* A majority of HIV persistence during antiretroviral therapy is
184 due to infected cell proliferation. *Nat Commun* **9**, 4811 (2018).
185 <https://doi.org/10.1038/s41467-018-06843-5>
- 186 57 McMyn, N. F. *et al.* The latent reservoir of inducible, infectious HIV-1 does not
187 decrease despite decades of antiretroviral therapy. *J Clin Invest* **133** (2023).
188 <https://doi.org/10.1172/JCI171554>
- 189 58 Massanella, M. *et al.* Long-term effects of early antiretroviral initiation on HIV
190 reservoir markers: a longitudinal analysis of the MERLIN clinical study. *Lancet*
191 *Microbe* **2**, e198-e209 (2021). [https://doi.org/10.1016/s2666-5247\(21\)00010-0](https://doi.org/10.1016/s2666-5247(21)00010-0)

- 192 59 Fromentin, R. *et al.* CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute
193 to HIV Persistence during ART. *PLoS Pathog* **12**, e1005761 (2016).
194 <https://doi.org/10.1371/journal.ppat.1005761>
- 195 60 Fromentin, R. *et al.* PD-1 blockade potentiates HIV latency reversal ex vivo in
196 CD4(+) T cells from ART-suppressed individuals. *Nat Commun* **10**, 814 (2019).
197 <https://doi.org/10.1038/s41467-019-08798-7>
- 198 61 Murray, J. M., Kelleher, A. D. & Cooper, D. A. Timing of the components of the
199 HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected
200 individuals. *J Virol* **85**, 10798-10805 (2011). <https://doi.org/10.1128/JVI.05095-11>
- 201 62 Gilmore, J. B., Kelleher, A. D., Cooper, D. A. & Murray, J. M. Explaining the
202 determinants of first phase HIV decay dynamics through the effects of stage-
203 dependent drug action. *PLoS Comput Biol* **9**, e1002971 (2013).
204 <https://doi.org/10.1371/journal.pcbi.1002971>
- 205 63 Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. HIV-
206 1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral
207 generation time. *Science* **271**, 1582-1586 (1996).
208 <https://doi.org/10.1126/science.271.5255.1582>
- 209 64 Markowitz, M. *et al.* A novel antiviral intervention results in more accurate
210 assessment of human immunodeficiency virus type 1 replication dynamics and T-
211 cell decay in vivo. *J Virol* **77**, 5037-5038 (2003).
212 <https://doi.org/10.1128/jvi.77.8.5037-5038.2003>

- 213 65 Shan, L. *et al.* Transcriptional Reprogramming during Effector-to-Memory
214 Transition Renders CD4(+) T Cells Permissive for Latent HIV-1 Infection.
215 *Immunity* **47**, 766-775 e763 (2017). <https://doi.org/10.1016/j.immuni.2017.09.014>
- 216 66 De Boer, R. J., Homann, D. & Perelson, A. S. Different dynamics of CD4+ and
217 CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus
218 infection. *J Immunol* **171**, 3928-3935 (2003).
219 <https://doi.org/10.4049/jimmunol.171.8.3928>
- 220 67 Zhan, Y., Carrington, E. M., Zhang, Y., Heinzl, S. & Lew, A. M. Life and Death
221 of Activated T Cells: How Are They Different from Naive T Cells? *Front Immunol*
222 **8**, 1809 (2017). <https://doi.org/10.3389/fimmu.2017.01809>
- 223 68 Siliciano, J. D. *et al.* Long-term follow-up studies confirm the stability of the latent
224 reservoir for HIV-1 in resting CD4+ T cells. *Nat Med* **9**, 727-728 (2003).
225 <https://doi.org/10.1038/nm880>
- 226 69 Crooks, A. M. *et al.* Precise Quantitation of the Latent HIV-1 Reservoir:
227 Implications for Eradication Strategies. *J Infect Dis* **212**, 1361-1365 (2015).
228 <https://doi.org/10.1093/infdis/jiv218>
- 229 70 Vandergeeten, C. *et al.* Cross-clade ultrasensitive PCR-based assays to
230 measure HIV persistence in large-cohort studies. *J Virol* **88**, 12385-12396 (2014).
231 <https://doi.org/10.1128/JVI.00609-14>
- 232 71 Finzi, D. *et al.* Identification of a reservoir for HIV-1 in patients on highly active
233 antiretroviral therapy. *Science* **278**, 1295-1300 (1997).
234 <https://doi.org/10.1126/science.278.5341.1295>

- 235 72 Procopio, F. A. *et al.* A Novel Assay to Measure the Magnitude of the Inducible
236 Viral Reservoir in HIV-infected Individuals. *EBioMedicine* **2**, 872-881 (2015).
237 <https://doi.org/10.1016/j.ebiom.2015.06.019>
- 238 73 Ho, Y. C. *et al.* Replication-competent noninduced proviruses in the latent
239 reservoir increase barrier to HIV-1 cure. *Cell* **155**, 540-551 (2013).
240 <https://doi.org/10.1016/j.cell.2013.09.020>
- 241 74 Eriksson, S. *et al.* Comparative analysis of measures of viral reservoirs in HIV-1
242 eradication studies. *PLoS pathogens* **9**, e1003174 (2013).
243 <https://doi.org/10.1371/journal.ppat.1003174>
- 244 75 Pollack, R. A. *et al.* Defective HIV-1 Proviruses Are Expressed and Can Be
245 Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.
246 *Cell Host Microbe* **21**, 494-506 e494 (2017).
247 <https://doi.org/10.1016/j.chom.2017.03.008>
- 248 76 Simon, V. & Ho, D. D. HIV-1 dynamics in vivo: implications for therapy. *Nat Rev*
249 *Microbiol* **1**, 181-190 (2003). <https://doi.org/10.1038/nrmicro772>
- 250 77 Siliciano, J. D. *et al.* Long-term follow-up studies confirm the stability of the latent
251 reservoir for HIV-1 in resting CD4+ T cells. *Nature medicine* **9**, 727-728 (2003).
252 <https://doi.org/10.1038/nm880>
- 253 78 Pinzone, M. R. *et al.* Longitudinal HIV sequencing reveals reservoir expression
254 leading to decay which is obscured by clonal expansion. *Nat Commun* **10**, 728
255 (2019). <https://doi.org/10.1038/s41467-019-08431-7>

- 256 79 Gondim, M. V. P. *et al.* Heightened resistance to host type 1 interferons
257 characterizes HIV-1 at transmission and after antiretroviral therapy interruption.
258 *Sci Transl Med* **13** (2021). [https://doi.org:10.1126/scitranslmed.abd8179](https://doi.org/10.1126/scitranslmed.abd8179)
- 259 80 Kinloch, N. N. *et al.* HIV-1 diversity considerations in the application of the Intact
260 Proviral DNA Assay (IPDA). *Nat Commun* **12**, 165 (2021).
261 [https://doi.org:10.1038/s41467-020-20442-3](https://doi.org/10.1038/s41467-020-20442-3)
- 262 81 Whitney, J. B. *et al.* Rapid seeding of the viral reservoir prior to SIV viraemia in
263 rhesus monkeys. *Nature* **512**, 74-77 (2014). [https://doi.org:10.1038/nature13594](https://doi.org/10.1038/nature13594)
- 264 82 Kumar, M. R. *et al.* Biphasic decay of intact SHIV genomes following initiation of
265 antiretroviral therapy complicates analysis of interventions targeting the reservoir.
266 *Proc Natl Acad Sci U S A* **120**, e2313209120 (2023).
267 [https://doi.org:10.1073/pnas.2313209120](https://doi.org/10.1073/pnas.2313209120)
- 268 83 Martin, A. R. *et al.* Similar Frequency and Inducibility of Intact Human
269 Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. *J Infect Dis*
270 **224**, 258-268 (2021). [https://doi.org:10.1093/infdis/jiaa736](https://doi.org/10.1093/infdis/jiaa736)
- 271 84 Simonetti, F. R. *et al.* Intact proviral DNA assay analysis of large cohorts of
272 people with HIV provides a benchmark for the frequency and composition of
273 persistent proviral DNA. *Proc Natl Acad Sci U S A* **117**, 18692-18700 (2020).
274 [https://doi.org:10.1073/pnas.2006816117](https://doi.org/10.1073/pnas.2006816117)
- 275 85 Bruner, K. M. *et al.* A quantitative approach for measuring the reservoir of latent
276 HIV-1 proviruses. *Nature* **566**, 120-125 (2019). [https://doi.org:10.1038/s41586-](https://doi.org/10.1038/s41586-019-0898-8)
277 [019-0898-8](https://doi.org/10.1038/s41586-019-0898-8)

278 86 Lehmann, E. L. & Casella, G. *Theory of point estimation*. Second edition. edn,
279 (Springer, 1998).

280

281

282 **FIGURE LEGENDS**

283 **Table 1. UCSF Treat Acute HIV Study Population.** Medians (with interquartile ranges) or
284 frequencies (with percentages) are shown.

285
286 **Fig. 1: The distribution of study participants in the UCSF Treat Acute HIV cohort.** A total of
287 67 participants met inclusion criteria for acute HIV, defined as <100 days since the estimated
288 date of detected HIV infection (EDDI) using the Infection Dating Tool (<https://tools.incidence-estimation.org/idt/>); these estimates were then used to estimate acute HIV Fiebig stages (a).^{47,48}
289 The majority of the cohort was of non-White self-reported race/ethnicity, consistent with national
290 trends for people incident acute HIV (b).⁴⁹

291
292
293 **Fig. 2: Semiparametric monophasic, biphasic, and triphasic generalized additive models**
294 **of HIV reservoir decay during weeks 0-24.** We performed bootstrapping to estimate the
295 Akaike information criteria (AIC) value and 95% confidence intervals and compared
296 monophasic, biphasic, and triphasic models for both HIV intact (left panels) and defective (right
297 panels) DNA assays (a). Using the triphasic models for HIV intact (left panel) and defective
298 (right panel) DNA, we then determined the optimal inflection point(s), τ , by minimizing the
299 predicted mean absolute error (MAE; top panels) using leave-one-out cross-validation or the
300 predicted mean squared error (MSE; bottom panels) (b). Red dots denote the optimal inflection
301 point(s), τ , for each model and prediction loss metric. For HIV intact DNA, the first (x-axis) and
302 second (y-axis) inflection points were relatively similar, suggesting that a single inflection point –
303 i.e., a biphasic model – adequately described the data. For HIV defective DNA, the first
304 inflection point (x-axis) was close to zero, this again suggested that a biphasic model
305 reasonably described the data.

306

307 **Fig. 3 Determination of optimal inflection points for HIV intact and defective DNA**
308 **biphasic decay models.** Using the biphasic models for HIV intact (left panel) and defective
309 (right panel) DNA, we then determined the optimal inflection point(s), τ , by minimizing the
310 predicted mean absolute error (MAE; top panels) using leave-one-out cross-validation or the
311 predicted mean squared error (MSE; bottom panels) (b). An inflection point of $\tau = 5$ weeks
312 (vertical dashed line) best fit decay patterns for both HIV intact (left panels) and defective (right
313 panels) DNA. Red dots denote the best τ for each model and prediction error metric.

314
315 **Fig. 4 Predicted decay patterns of HIV intact and defective DNA during acute treated HIV**
316 **from weeks 0-24.** Decay patterns for observed (thin grey lines) HIV intact and total defective
317 (a), as well as 3' and 5' defective (b) DNA closely fit with average model predictions (thick black
318 lines). Sampling timepoints are labeled on the x-axis (including a week 2 study visit during which
319 confirmatory HIV test results were disclosed). We estimated average predicted participant
320 decay rates by taking the mean of E_i (estimated time between HIV infection and ART initiation),
321 C_i (initial CD4+ T cell count), and V_i (\log_{10} pre-ART plasma viral load) across participants from
322 final models.

323
324 **Fig. 5 HIV intact and defective DNA decay patterns were associated with known clinical**
325 **factors associated with HIV reservoir size.** The observed HIV DNA data are shown as thin
326 grey lines for each participant, while the decay pattern for the model-predicted average
327 participant is shown as the thick black lines. Biphasic decay patterns for HIV intact (left panel)
328 and combined defective (3' plus 5', right panel) were faster among participants initiating ART
329 earlier (<30 days vs. 30-100 days) (a), with higher initial CD4+ T cell counts (shown by tertiles)
330 (b), and lower pre-ART viral load (shown by tertiles) (c).

331

332 **Fig. 6 Predicted HIV intact and defective DNA decay rates, by tertiles of clinical factors**
333 **associated with HIV reservoir size.** We performed bootstrapping to estimate the average
334 predicted decay rates of HIV intact (left panels) and defective (right panels) DNA, stratified by
335 tertiles of known clinical factors associated with HIV reservoir size: timing of ART initiation (a),
336 initial CD4+ T cell count (b), and pre-ART viral load (c).

337
338 **Supplementary Fig. 1: The UCSF Treat Acute HIV cohort study participants.** A total of 67
339 participants met inclusion criteria for acute HIV, defined as <100 days since the estimated date
340 of detected HIV infection (EDDI) using the Infection Dating Tool ([https://tools.incidence-](https://tools.incidence-estimation.org/idt/)
341 [estimation.org/idt/](https://tools.incidence-estimation.org/idt/)). The numbers of study participants by Fiebig stages (I-V) of HIV recency are
342 also shown ([https://doi.org:10.1097/01.aids.0000076308.76477.b8](https://doi.org/10.1097/01.aids.0000076308.76477.b8)). PrEP = Pre-exposure
343 prophylaxis with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).

344
345 **Supplementary Fig. 2: Calculation of estimated dates of detected HIV infection.** The
346 estimated dates of detected HIV infection (EDDI), along with a “confidence interval” for early
347 probable (EP-EDDI) and late probable (LP-EDDI) dates, were calculated using participants’
348 clinical test results as well as baseline study visit confirmatory assay results.

349
350 **Supplementary Fig. 3: HIV-1/2 test results for study participants.** The proportion of study
351 participants with either negative and/or indeterminate test results for HIV-1/2 p24
352 antigen/antibody assay (Architect) (a) and HIV-1/2 differentiation (Geenius) antibody assay (b)
353 at baseline study visit were consistent with rates with our San Francisco Department of Public
354 Health rates (27% and 28%, respectively).

355

356 **Supplementary Fig. 4: HIV intact and defective DNA decay patterns by self-reported**
357 **gender and prior PrEP use.** Observed HIV intact and defective DNA data, highlighting the one
358 cisgender female (yellow line) and one transgender female (blue line) participants (a).
359 Participants reporting PrEP use within 10 days of HIV diagnosis fell into two categories: 6
360 participants who acquired HIV while already taking PrEP (yellow lines), and 8 participants who
361 were found to already have acquired HIV at the time of PrEP initiation (blue lines). All other
362 study participants are shown as grey lines.

363
364 **Supplementary Fig. 5: Fine tuning of biphasic decay model inflection points from weeks**
365 **0-52.** A total of 65.7% of the study participants continued in follow-up beyond 24 weeks. We
366 further refined our estimates for the inflection point, τ , by testing sequential half-week windows
367 from 0 to 52 weeks and comparing the minimum prediction error using the leave-one-out mean
368 absolute error (MAE, upper panels) or the leave-one-out mean squared error (MSE, lower
369 panels). An inflection point of $\tau = 5$ weeks (vertical dashed line) remained the best fit decay
370 pattern for both HIV intact (left panels) and defective (right panels) DNA out to 52 weeks of
371 ART. Red dots denote the best τ for each model and prediction error metric.

372
373 **Supplementary Table 1. Model estimates for HIV intact and defective DNA reservoir**
374 **decay rates during acute treated HIV.** Slope and half-life ($t_{1/2}$) estimates of HIV intact and
375 defective decay rates for unadjusted (a-b) and adjusted models (b-c) during frequently sampled
376 timepoints (weeks 0-24; a, c) and extended out to one year (weeks 0-52; b, d). Adjusted models
377 included covariates for initial CD4+ T cell count, pre-ART HIV RNA, and timing of ART initiation.

378
379 **Supplementary Fig. 6: Predicted decay patterns of HIV intact and defective DNA during**
380 **acute treated HIV from weeks 0-52.** A total of 65.7% of the study participants continued in

381 follow-up beyond 24 weeks. Decay patterns for observed (thin grey lines) HIV intact (left panel)
382 and total defective (right panel) DNA closely fit with average model predictions (thick black
383 lines). Sampling timepoints are labeled on the x-axis (including a week 2 study visit during which
384 confirmatory HIV test results were disclosed). Average predicted participant predictions were
385 made by taking the mean of E_i (estimated time between HIV infection and ART initiation), C_i
386 (initial CD4+ T cell count), and V_i (\log_{10} pre-ART plasma viral load) across participants from final
387 models.

388

389 **Supplementary Fig. 7: Predicted versus observed plots show good model performance**
390 **for both HIV intact and defective DNA.** Validation for the final models for intact and defective
391 HIV DNA decay was initially performed by looking at the plots of predicted vs observed HIV
392 DNA counts. These plots show that both models produce relatively unbiased estimates across
393 the observed range of HIV DNA counts and that the residual variance in the defective reservoir
394 is much higher than the intact reservoir. Red dashed line denotes the idealized fit where
395 predicted values exactly equal observed values.

396

397 **Supplementary Fig. 8: Sensitivity analyses estimating HIV intact and defective DNA**
398 **decay rates after excluding potential outlier clinical subgroups.** The final model ($\tau = 5$
399 weeks) was fit on three clinically interesting sub-populations to assess if the influence of
400 potential outlier data. Separate models were fit that excluded (a) participants reporting prior
401 PrEP use (<10 days overlap between last PrEP use and estimated date of detected HIV
402 infection), (b) participants with plasma viral load “blips” (defined as a one-time viral load >1000
403 copies/mL or two consecutive viral loads >100 copies/mL between weeks 0-24), and (c)
404 participants with sudden increases in HIV intact DNA (defined as >50% increase between two
405 consecutive measurements of HIV intact DNA during weeks 0-24). Models were fit using the
406 cohort data (grey lines), but not the potential outlier data (red lines). The resulting predicted

407 average participant HIV reservoir decay patterns are shown as thick black lines. Refer to
408 **Supplementary Table 1** to get the sample sizes and half-life estimates for each sensitivity
409 analysis.

410

411 **Supplementary Fig. 9: Inflection point sensitivity analyses demonstrate some variability**

412 **when excluding populations of potential outliers.** To test whether the final model inflection

413 point selection of $\tau = 5$ weeks was influenced by potential outlier data we performed τ estimation

414 on three clinically interesting sub-populations. Separate models were fit that excluded (a)

415 participants reporting prior PrEP use (<10 days overlap between last PrEP use and estimated

416 date of detected HIV infection), (b) participants with plasma viral load “blips” (defined as a one-

417 time viral load >1000 copies/mL or two consecutive viral loads >100 copies/mL between weeks

418 0-24), and (c) participants with sudden increases in HIV intact DNA (defined as >50% increase

419 between two consecutive measurements of HIV intact DNA during weeks 0-24). A regular grid

420 of possible τ was used (0-26 weeks by half-week) and the leave-one-out cross-validation

421 (LOOCV) mean absolute prediction error (MAE) was computed for each candidate τ . Red dots

422 denote the best τ for each model and prediction error metric and our selected inflection point (τ

423 = 5) is shown with a dashed vertical line. Refer to **Supplementary Table 1** to get the sample

424 size for each sensitivity analysis and to **Supplementary Fig. 9** to see which patients are

425 excluded from each sensitivity analysis.

426

427 **Supplementary Table 2. Sensitivity analyses of HIV intact and defective DNA reservoir**

428 **decay rates during acute treated HIV.** Slope and half-life estimates of HIV intact and defective

429 decay rates after excluding participants reporting prior preexposure prophylaxis (PrEP) use

430 within 10 days of estimated date of HIV infection (a), participants with plasma viral load “blips”

431 (defined as a one-time viral load >1000 copies/mL or two consecutive viral loads >100

432 copies/mL between weeks 0-24) (b), and participants with sudden increases in HIV intact DNA
433 (defined as >50% increase between two consecutive measurements of HIV intact DNA during
434 weeks 0-24) (c). All models were adjusted for initial CD4+ T cell count, pre-ART HIV RNA, and
435 timing of ART initiation.

436

437 **Supplementary Table 3. The effect of earlier ART initiation on HIV intact and defective**
438 **DNA decay rates.** We performed bootstrapping to calculate the difference in half-life estimates
439 for HIV intact and defective DNA, with each week that ART is initiated earlier. All models were
440 adjusted for initial CD4+ T cell count and pre-ART HIV RNA.

441

442 **Supplementary Table 4. The effect of higher initial CD4+ T cell count or lower pre-ART**
443 **HIV RNA on HIV intact and defective DNA decay rates.** We performed bootstrapping to
444 calculate average half-life estimates for HIV intact and defective DNA for each quartile change
445 in initial CD4+ T cell count or pre-ART HIV RNA. Models estimating the effect of initial CD4+ T
446 cell count were adjusted for timing of ART initiation and pre-ART HIV RNA. Models estimating
447 the effect of pre-ART HIV RNA were adjusted for timing of ART initiation and initial CD4+ T cell
448 count.

449

450 **Supplementary Fig. 10: Fitted spline models to estimate the effect of higher initial CD4+ T**
451 **cell count or lower pre-ART HIV RNA on HIV intact and defective DNA decay rates.** Fitted
452 spline models (red lines) with corresponding 95% confidence intervals (blue dashed lines) are
453 shown for HIV intact DNA (a) and HIV defective (b) DNA. Plots are shown for pre-ART HIV RNA
454 (left panels) and initial CD4+ T cell count (right panels).

455

456 **Supplementary Fig. 11: Semiparametric monophasic, biphasic, and triphasic generalized**
457 **additive models of plasma HIV RNA decay during weeks 0-24.** We performed bootstrapping

458 to estimate the Akaike information criteria (AIC) value and 95% confidence intervals and
459 compared monophasic, biphasic, and triphasic models for plasma HIV RNA (a). Using the
460 triphasic model for plasma HIV RNA, we then determined the optimal inflection point(s), τ , by
461 minimizing the predicted mean absolute error (MAE; top panel) using leave-one-out cross-
462 validation or the predicted mean squared error (MSE; bottom panel) (b). Red dots denote the
463 optimal inflection point(s), τ , for the model and loss metric. These analyses demonstrated an
464 inflection point at 0.5 weeks (red dot at x-axis) and 4 weeks (red dot at y-axis), suggesting that a
465 triphasic model best fit the data (b).

466

467 **Supplementary Table 5. Model estimates of plasma HIV RNA decay rates during acute**
468 **treated HIV.** Slope and half-life ($t_{1/2}$) estimates of plasma HIV RNA decay rates for models
469 adjusted for initial CD4+ T cell count and timing of ART initiation during frequently sampled
470 timepoints (weeks 0-24). Models included a random intercept for each participant. We
471 calculated estimates for each phase of the final triphasic decay model: 0 to 0.5 weeks, 0.5-4
472 weeks, and 4-24 weeks. We did not observe a statistically significant decay of plasma HIV RNA
473 after week 4, given that the majority of participants had undetectable plasma HIV RNA levels
474 after a median of 4.14 weeks on ART.

475

476 **Supplementary Fig. 12: Predicted versus observed plots demonstrating model**
477 **performance for plasma HIV RNA.** Validation for the final model for plasma HIV RNA decay
478 was initially performed by looking at the plots of predicted vs observed plasma HIV RNA counts.
479 This plot shows that the triphasic model produces unbiased estimates for a large range of
480 plasma HIV RNA counts. The model systematically underestimates very large plasma HIV RNA
481 values and has high variability at very low plasma HIV RNA values (e.g., <40 copies/mL). Red
482 dashed line denotes the idealized fit where predicted values exactly equal observed values.

483

484 **Supplementary Fig. 13: Plasma HIV RNA decay patterns were associated with known**
485 **clinical factors associated with HIV reservoir size.** The observed plasma HIV RNA data are
486 shown as thin grey lines for each participant. Plasma HIV RNA decay was faster among
487 participants initiating ART earlier (<30 days vs. 30-100 days) (a) and with higher initial CD4+ T
488 cell counts (shown by tertiles) (b).

489

490 **Supplementary Fig. 14: Predicted plasma HIV RNA decay rates, by tertiles of clinical**
491 **factors associated with HIV reservoir size.** We performed bootstrapping to estimate the
492 average predicted decay rates of plasma HIV RNA, stratified by known clinical factors
493 associated with HIV reservoir size: timing of ART initiation (a) and initial CD4+ T cell count (b).

494

495 **Supplementary Fig. 15: Fitted spline models to estimate the effect of higher initial CD4+ T**
496 **cell count on plasma HIV RNA decay rate.** Fitted spline model (red line) with corresponding
497 95% confidence interval (blue dashed line) is shown for plasma HIV RNA in relation to initial
498 CD4+ T cell count.

499